{"nctId":"NCT00086502","briefTitle":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2004-06"},"conditions":["Diabetes Mellitus, Type 2"],"count":353,"armGroups":[{"label":"Sitagliptin 100 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: Sitagliptin","Drug: Comparator: Pioglitazone","Drug: Metformin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo","Drug: Comparator: Pioglitazone","Drug: Metformin"]}],"interventions":[{"name":"Comparator: Sitagliptin","otherNames":["Januvia"]},{"name":"Comparator: Placebo","otherNames":[]},{"name":"Comparator: Pioglitazone","otherNames":["ACTOS"]},{"name":"Metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus (T2DM)\n* Patient is 18 years of age (or older)\n* Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period\n\nExclusion Criteria:\n\n* Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis\n* Patient required insulin within the prior 8 weeks\n* Patient is on a weight loss program and is not in the maintenance phase\n* Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks\n* Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate)\n* Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease\n* Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis)\n* Patient has any of the following disorders within the past 6 months:\n\nAcute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke or transient ischemic neurological disorder.\n\n* Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months\n* Patient has severe peripheral vascular disease\n* Patient has congestive heart failure\n* Patient is HIV positive\n* Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n* Patient has a history of neoplastic disease\n* Patient has a history of alcohol or drug abuse within the past 3 years\n* Patient has viral hepatitis (hepatitis B or C)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24","description":"HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.85","spread":null},{"groupId":"OG001","value":"-0.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24","description":"Change from baseline at Week 24 is defined as Week 24 minus Week 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.7","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":175},"commonTop":["Any Infections And Infestations","Upper Respiratory Tract Infection","Any Nervous System Disorders","Headache"]}}}